Sino Biopharmaceutical
Sino Biopharmaceutical
Sino Biopharmaceutical is a leading Chinese innovative research and R&D-driven pharmaceutical group
Sino Biopharmaceutical, founded in 2020 and headquartered in Hong Kong, is the leading innovative research and R&D-driven pharmaceutical group in China, with a business scope that covers the entire industry chain of pharmaceutical R&D platforms, intelligent production, and strong sales systems. Established by Xie Qirun, it was listed on the Hong Kong Stock Exchange In September of the same year as the foundation. The company's major shareholders are Thousand Eagles Limited, FRANCE INVESTMENT (CHINA 1) GROUP LIMITED, Remarkable Industries Limited, and Validated Profits Limited. Rivals with the direct and indirect competition with Sino Biopharmaceutical include Lansen Pharmaceutical, Chia Tai Enterprises, Hansoh Pharma.
- All
- News
- Analysis
- Research
Briefing Jan 10, 2022 11:16 AM
· Healthcare
Lanjing microorganism completed a total of RMB 1.5 billion of Series B financing and accelerated the implementation of the "T-type" development strategy
Briefing Jan 06, 2022 03:39 PM
· Healthcare
Xinmai medical announced strategic cooperation with rainbow medical, a famous medical device incubator in Israel
In depth
Briefing Jan 06, 2022 11:27 AM
· Healthcare
Hengrui medicine has been introduced for more than US $100 million! New antifungal drugs applied for listing in China
Briefing Jan 06, 2022 09:28 AM
· Healthcare
Jiangsu new element medicine completed a round C financing of more than 300 million yuan, and the gout innovative medicine has a good curative effect
Research
Healthcare, Technology, Consumer StaplesWIA2020 | Rising Tech Stars 2020: Global & China's 100
Dec 09, 2020 09:57 AM
Dec 09, 2020 09:39 AM
Research
Real Estate, Industrials, FinancialsTech for Global, Globalization Footprints of the Established and the New
May 29, 2020 08:30 PM
Research
Real Estate, Industrials, FinancialsLow-Carbon Industry Expansion - Key Studies From Chinese Companies
May 28, 2020 12:40 PM
Briefing Jan 06, 2022 09:26 AM
· Healthcare
Jiayue pharmaceutical completed nearly 200 million yuan of B + round financing and promoted the mid and late stage clinical projects of innovative drug pipeline
Briefing Dec 31, 2021 06:27 PM
· Healthcare
The IPO of Lianying medical technology innovation board has been accepted by Shanghai Stock Exchange
Briefing Dec 31, 2021 05:55 PM
· Healthcare
Hengrui pharmaceutical CDK4 / 6 inhibitor approved! Treatment of advanced breast cancer
Briefing Dec 31, 2021 05:52 PM
· Healthcare
Hengrui pharmaceutical sglt-2 inhibitor hengglijing was approved in China
In depth
Healthcare
Dada group's revenue rose nearly 30% in the third quarter, and JD's "hour purchase" cont
Looking forward to the fourth quarter of 2021, dada Group expects its total revenue to be between 2 billion yuan and 2.1 billion yuan. On the premise that the last kilometer of dada express delivery service is consistent with the comparable basis, the total revenue in the fourth quarter of 2021 will achieve a year-on-year increase of 88% to 97%.
Nov 24, 2021 11:42 AM
Briefing Dec 31, 2021 02:06 PM
· Healthcare
The first KRAS concomitant diagnostic PCR kit in China was approved for marketing
Briefing Dec 31, 2021 02:00 PM
· Healthcare
China's new crown oral drug vv116 has been authorized for emergency use in Uzbekistan
Briefing Dec 31, 2021 01:57 PM
· Healthcare
Wu Kun, chief operating officer of Pfizer China, will leave
Insight
Briefing Dec 31, 2021 01:55 PM
· Healthcare
Samsung Bio said the acquisition of Bojian was untrue
Briefing Dec 30, 2021 08:58 AM
· Healthcare
Jdb175 and jdb153 tablets, a class I new drug of Jiabao Yaoyin, have been approved for clinical trial by China food and drug administration
Briefing Aug 18, 2021 07:54 PM
Jin Litai: the prices of various types of cathodic electrophoretic paint products rise by 10% - 20%
See more
Related Companies
EqualOcean Analysis
- Black Swans and Breakthroughs: China's Top 50 Innovative Public Firms in 2020
- After China's BNR and GTH Hit Nasdaq, Pan-Cancer Detector GRAIL Eyes IPO
- Bid for Molecular Tech in China's Early-Stage Cancer Detection Market
- More Room for the Medical Device Market to Grow in China
- Modern Chinese Medicine Maker Tasly Pharmaceutical: An Old Stock in a New Package?
EqualOcean is an information service provider and investment research company that aims to become a global platform for industrial innovation. Founded in February 2014 and headquartered in Beijing, with a client network covering over 50 countries, the firm provides comprehensive professional services, including industry research, investment analysis, innovation consulting, data products, corporate branding and international strategy.